Results 91 to 100 of about 164 (107)

New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series

Multiple Sclerosis Journal
Lymphopenia is a known adverse effect in patients with relapsing multiple sclerosis (RMS) treated with fumaric acids. We present a case series of four patients diagnosed with RMS with prolonged lymphocyte stability on dimethyl fumarate for over 1 year who developed significant lymphopenia after transitioning to diroximel fumarate.
Megan Schneider, John Kramer
exaly   +3 more sources

Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study

Advances in Therapy, 2019
Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact adisrapidplus@springer.com.
Catherine Miller
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Herpes zoster infection in a patient with relapsing-remitting multiple sclerosis treated with diroximel fumarate

BMJ Case Reports
We present a case of a woman in her 50s with relapsing-remitting multiple sclerosis, treated with diroximel fumarate, who developed an itching, burning vesicular rash following a C3 dermatomal distribution on her left face and neck. She was diagnosed with herpes zoster, treated with valacyclovir and gabapentin, and made a full recovery.
John Dempsey, Alexandra Balshi, Jacob Sloane   +2 more
openaire   +2 more sources

Diroximel Fumarate Pregnancy Outcomes in EVOLVE-MS-1 and Study Design of Diroximel Fumarate Prospective MS Pregnancy Exposure Registry (P9-3.003)

Neurology, 2023
Maria Houtchens, Annette Wundes, Benjamin Osborne, Ivan Bozin, Filipe Branco, Hailu Chen, Sarah England, Nancy Gerber, Seth Levin, Xiaochen Lin, Matthew Scaramozza, Kerstin Hellwig   +11 more
openaire   +1 more source

Opioid-sparing Effects of the Nrf2 Activator Diroximel Fumarate in Mice

The Journal of Pain, 2022
Mohd Sami Ur Rasheed, Fisher R. Cherry, Peter M. Grace   +2 more
openaire   +1 more source

Diroximel-fumarate/natalizumab

Reactions Weekly, 2023
openaire   +1 more source

Diroximel Fumarate and Dimethyl Fumarate Demonstrate Early Radiological Efficacy in Relapsing-remitting Multiple Sclerosis (2190)

Neurology, 2021
Barry A. Singer, S. James Shafer, Douglas L. Arnold, James D. Bowen, Christopher LaGanke, Hailu Chen, Matthew Scaramozza, Jordan Messer, Robert T. Naismith   +8 more
openaire   +1 more source

Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis

Neurology and Therapy, 2022
Mita Kuchimanchi
exaly  

Improved Gastrointestinal Tolerability Profile with Diroximel Fumarate Compared to Dimethyl Fumarate in Relapsing MS Patients (994)

Neurology, 2020
Annette Wundes, Jerry S. Wolinsky, Sibyl Wray, Tjalf Ziemssen, Elzbieta Jasinska, Mark S. Freedman, Ilda Bidollari, Hailu Chen, Jerome Hanna, Richard Leigh-Pemberton, Jennifer Lyons, Jordan Messer, Robert T. Naismith   +12 more
openaire   +1 more source

Diroximel fumarate and dimethyl fumarate demonstrate early clinical and radiological efficacy in relapsing-remitting multiple sclerosis (1337)

Neurology, 2020
Barry A. Singer, S. James Shafer, Douglas L. Arnold, James D. Bowen, Christopher LaGanke, Hailu Chen, Jerome Hanna, Catherine Miller, Richard Leigh-Pemberton, Robert T. Naismith   +9 more
openaire   +1 more source